From 21^st to 23^rd September 2022, the “7^th China Pharma IP Summit 2022”, which is jointly organized by YIP Events and IP ForeFront, is convened in Suzhou, Jiangsu Province.

Themed “BioPharma IP planning, challenge and opportunity of the new era”, the Summit boasts a strong 56 speakers from domestic and oversea practitioners in pharmaceuticals and life sciences industry, research institutes and law firms.

The Summit features a pre-summit session addressing an array of topics including licensing, collaborative development, trade secret, commercialization and IP pledging, biopharma patent application in EU and US, patent enforcement practice, and four panel discussions centering “Patent data analysis, patent linkage practice & strategy”, “Patent term extension regime, reverse payment & compliance”, “Inventiveness assessment, supplementary experimental data, re-examination invalidity cases, antibody & infringement proceeding”, as well as “Cell therapy, ADC drug, gene editing technique, IP portfolio of frontier technology and FTO”.

Wanhuida Intellectual Property Partner Tang Tiejun moderates the panel discussion on “Inventiveness assessment, supplementary experimental data, re-examination invalidity cases, antibody & infringement proceeding”. Tiejun and the firm’s another Partner Wang Yuming give a joint presentation on “Hot-button issues in BioPharma patent infringement proceeding & coping strategy thereof”. The firm’s Partner Minnan (Miranda) Xie also attends the summit.

The event attracts a full house of participants from Chinese and foreign biopharma corporations, industry associations and leading law firms.

IP ForeFront is a media information platform operated by Shanghai YIP Events Co., Ltd. Specialized in intellectual property, IP ForeFront features in-depth, high-quality and original IP policy insights, case analysis, and updates.

Tang Tiejun

Wang Yuming

Minnan (Miranda) Xie, Wang Yuming and Tang Tiejun (L to R)